Advertisement
COYA vs EDIT
Which Stock Would AI Choose? Coya Therapeutics (COYA) vs. Editas Medicine (EDIT) Stock Comparison
Key Takeaways
- Two distinct biotech bets: COYA targets neuroinflammation through regulatory T-cell biology, while EDIT develops CRISPR-based gene editing.
- Financial cushion differs sharply: EDIT holds roughly $211 million in cash with a runway into the second half of 2028, compared with COYA's approximately $50 million.
- Catalyst profiles diverge: EDIT recently secured regulatory clearance to begin a Phase 1/2 trial in Australia, while COYA is advancing its ALSTARS Phase 2 ALS study.
- Analyst sentiment favors COYA with a consensus "Strong Buy" and a higher average price target relative to current price, while EDIT's coverage is more mixed.
- Relative performance has shifted: EDIT posted strong year-to-date gains but has pulled back in recent weeks, while COYA has traded in a comparatively narrow, low range.
- For deeper coverage, explore COYA Major News and COYA Today's Price Move, as well as EDIT Major News and EDIT Today's Price Move.
- To see how automated strategies are navigating these and other tickers, visit Trending AI Robots.
Introduction
Clinical-stage biotechnology stocks like COYA and EDIT offer high-upside, high-risk exposure driven less by current earnings than by pipeline milestones, regulatory events, and balance-sheet durability. Coya Therapeutics and Editas Medicine both operate without approved products, making their valuations highly sensitive to clinical and financing news. This comparison is most relevant to traders and investors who track momentum and catalyst-driven moves in the biotech sector, as well as to those evaluating how cash runways and regulatory progress shape relative performance and market positioning.
COYA Overview and Recent Performance
COYA (Coya Therapeutics) is a Houston-based, clinical-stage biotech developing therapies aimed at restoring the anti-inflammatory function of regulatory T cells (Tregs), a type of immune cell implicated in neurodegenerative, metabolic, and autoimmune disease. Its lead candidate, COYA 302, combines low-dose IL-2 (interleukin-2) with CTLA-4 Ig to address ALS (amyotrophic lateral sclerosis) and other neurological conditions.
In recent weeks, the company has focused on its ALSTARS Phase 2 ALS trial, announcing an expansion of its inclusion criteria designed to broaden the patient population and accelerate recruitment. These updates build on a broader development strategy that includes a licensing partnership with Dr. Reddy's Laboratories. Financially, COYA reported about $50.7 million in cash as of the end of the first quarter of 2026, with a modest net loss of roughly $7.2 million. The stock has remained in a relatively low price range, trading well below its 52-week high, and carries a consensus "Strong Buy" rating from analysts with an average price target meaningfully above its recent price. Sentiment has been shaped by both the clinical catalysts ahead and ongoing questions about the company's cash runway.
EDIT Overview and Recent Performance
EDIT (Editas Medicine) is a Cambridge, Massachusetts-based genome-editing company focused on CRISPR/Cas9 and CRISPR/Cas12 technologies. After discontinuing its reni-cel sickle cell and beta-thalassemia program, the company has prioritized EDIT-401, an experimental one-time in vivo (inside the body) gene-editing therapy that targets the LDLR gene for heterozygous familial hypercholesterolemia (HeFH), an inherited condition marked by dangerously high LDL cholesterol.
Recent market activity has centered on the program's first-in-human progress: Editas received approval to initiate a Phase 1/2 trial in Australia, a key de-risking milestone that moved shares in recent weeks. The company reported roughly $211.6 million in cash and investments as of mid-2026, which it expects to fund operations into the second half of 2028. Quarterly revenue rose year over year to about $11.9 million, largely from deferred collaboration revenue. Despite a strong year-to-date advance, EDIT has pulled back in recent weeks and now trades below its 20-day moving average, reflecting volatility around both broader biotech sentiment and program-specific expectations.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that collectively trade thousands of different tickers, each built around its own trading style, strategy, timeframe, and performance statistics. Because market conditions shift constantly, only a select group of these bots is featured in Tickeron's curated Trending AI Robots section. This shortlist is designed to spotlight the strategies currently best suited to prevailing market dynamics, whether they favor momentum, mean reversion, or other algorithmic approaches. For traders comparing names like COYA and EDIT, these bots can provide an additional, data-driven perspective on relative positioning. If you are interested in how automation interprets today's market, consider reviewing the Trending AI Robots list.
Head-to-Head Comparison
Although both companies are clinical-stage biotechs, their business models target fundamentally different biology. COYA operates in immunology and neuroinflammation, aiming to modulate existing immune pathways through Treg biology, while EDIT pursues durable, one-time fixes through gene editing. This distinction shapes their risk profiles: EDIT's approach carries the execution and safety risk inherent in editing DNA, whereas COYA's biological approach depends on validating immune-modulation endpoints in complex neurological diseases.
The clearest contrast is financial durability. EDIT's larger cash balance and longer runway provide more time to reach clinical readouts without immediate dilution, while COYA's smaller reserve creates greater sensitivity to financing decisions and near-term clinical outcomes. On the catalyst side, EDIT has a discrete, near-term regulatory milestone already achieved in Australia, whereas COYA's value hinges on slower-moving ALS trial enrollment and data. Market sentiment reflects this asymmetry: analysts are collectively more bullish on COYA's risk-reward, while EDIT's shares have demonstrated higher volatility and stronger year-to-date momentum that has recently cooled.
Tickeron AI Verdict
Based on observable factors including trend consistency, catalyst visibility, and balance-sheet stability, Tickeron's AI would likely assign a modest current edge to EDIT. The company's substantially longer cash runway, larger market capitalization, and a concrete regulatory approval to begin human trials provide a more stable foundation amid sector volatility. By contrast, COYA benefits from stronger consensus analyst enthusiasm and a high-upside clinical narrative, but its thinner cash position introduces additional near-term execution risk. This assessment is probabilistic rather than definitive, and the relative outlook could shift quickly as new clinical data and financing events emerge for either company.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COYA is a Hold and EDIT is a Hold.
COYA in downward trend: 10-day moving average moved below 50-day moving average on October 14, 2026
The 10-day moving average for COYA crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
COYA moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for COYA moved below the 200-day moving average on October 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for COYA entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where COYA's RSI Oscillator exited the oversold zone, 26 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 40 of 48 cases where COYA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
Following a +18.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where COYA advanced for three days, in 168 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
COYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.621) is normal, around the industry mean (3.498). P/E Ratio (-2.794) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (11.062) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. COYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Aroon Indicator for EDIT shows an upward move is likely
EDIT's Aroon Indicator triggered a bullish signal on November 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 154 similar instances where the Aroon Indicator showed a similar pattern. In 128 of the 154 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.498). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
EDIT | ||
|---|---|---|
OUTLOOK RATING 1..100 | 73 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 53 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 71 | |
P/E GROWTH RATING 1..100 | 30 | |
SEASONALITY SCORE 1..100 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| COYA | EDIT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | N/A |
| Stochastic ODDS (%) | 1 day ago 83% | 1 day ago 77% |
| Momentum ODDS (%) | N/A | 1 day ago 90% |
| MACD ODDS (%) | N/A | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 83% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 89% |
| Advances ODDS (%) | 3 days ago 86% | 3 days ago 80% |
| Declines ODDS (%) | 7 days ago 86% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 61% | 1 day ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COYA’s FA Score shows that 1 FA rating(s) are green while EDIT’s FA Score has 1 green FA rating(s).
- COYA’s FA Score: 1 green, 4 red.
- EDIT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COYA’s TA Score shows that 4 TA indicator(s) are bullish while EDIT’s TA Score has 3 bullish TA indicator(s).
- COYA’s TA Score: 4 bullish, 5 bearish.
- EDIT’s TA Score: 3 bullish, 6 bearish.
Price Growth
COYA (@Biotechnology) experienced а +1.61% price change this week, while EDIT (@Biotechnology) price change was -12.50% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
COYA is expected to report earnings on Nov 11, 2026.
EDIT is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
COYA and
Correlation & Price change
A.I.dvisor indicates that over the last year, COYA has been loosely correlated with EDIT. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if COYA jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To COYA | 1D Price Change % | ||
|---|---|---|---|---|
| COYA | 100% | +1.58% | ||
| EDIT - COYA | 51% Loosely correlated | -4.99% | ||
| VIR - COYA | 48% Loosely correlated | -0.15% | ||
| INMB - COYA | 44% Loosely correlated | N/A | ||
| CADL - COYA | 44% Loosely correlated | -1.39% | ||
| RXRX - COYA | 44% Loosely correlated | +1.13% | ||
More | ||||
EDIT and
Correlation & Price change
A.I.dvisor indicates that over the last year, EDIT has been closely correlated with BEAM. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To EDIT | 1D Price Change % | ||
|---|---|---|---|---|
| EDIT | 100% | -4.99% | ||
| BEAM - EDIT | 67% Closely correlated | +2.62% | ||
| CRSP - EDIT | 63% Loosely correlated | +1.33% | ||
| SLDB - EDIT | 62% Loosely correlated | +6.00% | ||
| PRME - EDIT | 61% Loosely correlated | +10.26% | ||
| VYGR - EDIT | 61% Loosely correlated | -3.56% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| HFMF | 21.96 | 0.27 | +1.24% |
| Unlimited HFMF Managed Futures ETF (HFMF) | |||
| GCV | 3.85 | 0.01 | +0.26% |
| Gabelli Convertible and Income Securities Fund (The) | |||
| GCSH | 49.84 | 0.09 | +0.18% |
| Guggenheim Ultra Short Income ETF (GCSH) | |||
| MAYC | 26.38 | N/A | N/A |
| Corgi U.S. Equities 10% Structured Buffer ETF (MAYC) | |||
| CORP | 92.94 | -0.02 | -0.02% |
| PIMCO Investment Grade Corporate Bond Index ETF (CORP) | |||